Management of Hypercalcemia of Malignancy

Primary First‑Line Therapy

The 2023 Endocrine Society guidelines recommend intravenous bisphosphonates (e.g., zoledronic acid 4 mg) or denosumab (120 mg) as the first‑line treatment for adults with hypercalcemia of malignancy; hydrocortisone is not listed as a standard option. 1

Treatment of Severe Hypercalcemia (Serum Calcium ≥ 14 mg/dL)

For patients with severe hypercalcemia, the Endocrine Society advises adding calcitonin (80–160 units per day) to the IV bisphosphonate or denosumab regimen for a maximum of 48–72 hours to achieve a more rapid calcium reduction; continuation beyond 72 hours is discouraged because of tachyphylaxis. 1

Practical Treatment Algorithm (Endocrine Society, 2023)

Step 1 – Confirm etiology (malignancy‑associated versus other causes such as sarcoidosis, adrenal insufficiency, or primary hyperparathyroidism). 1

Step 2 – Initiate first‑line therapy with IV zoledronic acid 4 mg *or denosumab 120 mg; do not* use hydrocortisone as primary treatment. 1

Step 3 – If calcium is ≥ 14 mg/dL, add calcitonin 80–160 units/day for up to 72 hours; discontinue thereafter to avoid tachyphylaxis. 1

Step 4 – Reserve hydrocortisone only for specific non‑malignancy scenarios (e.g., adrenal crisis or sarcoidosis), which are outside the Endocrine Society’s hypercalcemia‑of‑malignancy recommendations. 1